Morgan Stanley upgrades Torrent Pharma to Overweight, sees about 39.6% upside to Rs 5,623
AI Market Summary
Morgan Stanley upgraded Torrent Pharmaceuticals to "Overweight" and raised its target price, citing faster-than-expected JB Pharma integration synergies and strong positioning in India's GLP-1 therapies. It simultaneously downgraded Mankind Pharma to "Equalweight" on valuation after recent outperformance. The news is stock-specific, potentially driving near-term relative rotation within Indian pharma rather than broad macro or cross-asset repricing.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.16%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Morgan Stanley upgraded Torrent Pharmaceuticals to “Overweight” from “Equalweight” and lifted its target price to Rs 5,623, implying about 39.6% upside. The brokerage said cost synergies have already moved beyond the initial Rs 900 million target and are now expected to exceed Rs 1 billion, before rising to around Rs 3 billion in FY28 and nearly Rs 4.5 billion in FY29. It also highlighted Torrent’s position in India’s semaglutide market, with a 36% share overall and 94% in oral semaglutide.
